Meeting
2018 Gastrointestinal Cancers Symposium
The nationwide screening project on plasma angiogenesis-related mediators for treatment selection of optimal antiangiogenic inhibitors in metastatic colorectal cancer: GI-SCREEN CRC-Ukit.
Authors
Satoshi Yuki
Hokkaido University Hospital, Sapporo, Japan
Satoshi Yuki , Kentaro Yamazaki , Hiroya Taniguchi , Yu Sunakawa , Akihito Kawazoe , Yoshinori Kagawa , Ken Kato , Hiroki Hara , Tadamichi Denda , Eiji Oki , Toshikazu Moriwaki , Manabu Shiozawa , Taroh Satoh , HIsato Kawakami , Taito Esaki , Junji Furuse , Yukiko Abe , Shogo Nomura , Atsushi Ohtsu , Takayuki Yoshino
Organizations
Hokkaido University Hospital, Sapporo, Japan, Shizuoka General Hospital Cancer Center, Shizuoka, Japan, Aichi Cancer Center Hospital, Nagoya, Japan, St. Marianna University School of Medicine, Kawasaki, Japan, National Cancer Center Hospital, Chiba, Japan, Kansai Rosai Hospital, Amagasaki, Japan, National Cancer Center Hospital, Tokyo, Japan, Saitama Cancer Center, Saitama, Japan, Chiba Cancer Center, Chiba, Japan, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan, University of Tsukuba, Tsukuba, Japan, Kanagawa Cancer Center, Yokohama, Japan, Osaka University Graduate School of Medicine, Osaka, Japan, Kindai University, Osaka, Japan, National Kyushu Cancer Center, Fukuoka, Japan, Kyorin University, Tokyo, Japan, G&G Science Co., Ltd., Fukushima, Japan, National Cancer Center Hospital East, Chiba, Japan, National Cancer Center Hospital East, Kashiwa, Japan
Research Funding
Other Foundation
Background: Antiangiogenic treatments are a proven useful tool to improve clinical outcomes in patients (pts) with metastatic colorectal cancer (mCRC). Recently, higher levels of vascular endothelial growth factor-D (VEGF-D) are a potential predictive biomarker for ramucirumab efficacy on overall and progression-free survival in mCRC (Tabernero J, et al. ESMO 2017). However, there are limited data on mCRC associating the efficacy of antiangiogenic therapy with angiogenesis-related mediators, such as VEGF family members and their receptors, and with dynamic transition among these mediators during clinical courses. In addition, immune-related factors such as interferon gamma (IFNγ) and transforming growth factor β1 (TGFβ1) may be associated with the regulation of angiogenesis. Methods: This prospective longitudinal study aims to investigate the association between plasma angiogenesis-related mediators and clinical outcomes in mCRC. The key eligibility criteria include pts with mCRC who will receive one of the following regimens: first-line chemotherapy plus bevacizumab, first-line chemotherapy plus anti-EGFR antibody (either cetuximab or panitumumab), second-line FOLFIRI plus ramucirumab, second-line FOLFIRI plus aflibercept, or second-line chemotherapy plus bevacizumab. Plasma is collected twice in pairs from all pts pre- and post-treatment. Comprehensive measurements of plasma angiogenesis-related mediators, such as placental growth factor (PlGF), hepatocyte growth factor (HGF), IL-6, IL-8, angiopoietin-2, neuropillin-1, tissue inhibitor of metalloproteinase-1 (TIMP-1), soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), thrombospondin-2 (TSP-2), osteopontin (OPN), sVEGFR-1, sVEGFR-2, sVEGFR-3, VEGF-A, VEGF-D, as well as key targets associated with immunotherapy such as IFNγ and TGFβ1 are analyzed in parallel by the multiplex assay with Luminex® technology. The target sample size is 1,000. This study was initiated in September 2017. Clinical trial information: UMIN000028616.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
UMIN000028616
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr TPS885)
DOI
10.1200/JCO.2018.36.4_suppl.TPS885
Abstract #
TPS885
Poster Bd #
Q13
Abstract Disclosures
Similar Abstracts
Abstract
2022 ASCO Annual Meeting
Analysis of plasma angiogenesis factors on the efficacy of first-line (1L) chemotherapy (chemo) combined with biologics in RAS wild-type metastatic colorectal cancer (mCRC): Results from GI-SCREEN CRC Ukit study.
First Author: Satoshi Yuki
Abstract
2023 ASCO Annual Meeting
VIC regimen (vemurafenib/irinotecan/cetuximab) versus bevacizumab plus chemotherapy as first-line treatment for BRAF V600E-mutated advanced colorectal cancer.
First Author: Yijiao Chen
Abstract
2024 ASCO Gastrointestinal Cancers Symposium
Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study.
First Author: Thierry Andre
Abstract
2023 ASCO Gastrointestinal Cancers Symposium
Phase III FIRE-4 study (AIO KRK-0114): Evaluation of first-line treatment efficacy of FOLFIRI/cetuximab in patients with RAS-WT mCRC receiving the first cycle of treatment with chemotherapy only.
First Author: Sebastian Stintzing